labarai

Lokacin da dihydrotanshinone I ya kashe Helicobacter pylori, ba zai iya lalata biofilm kawai ba, har ma yana kashe ƙwayoyin cuta da ke haɗe da biofilm, wanda ke taka rawa wajen “tumɓuke” Helicobacter pylori.

Bi Hongkai, Farfesa, Makarantar Magungunan Asali, Jami'ar Kiwon Lafiya ta Nanjing

Sabbin bayanan cutar kanjamau na duniya sun nuna cewa daga cikin sabbin masu cutar kansa miliyan 4.57 a China kowace shekara, sabbin cututtukan 480,000 na ciwon daji na ciki, wanda ya kai kashi 10.8%, suna cikin manyan ukun. A kasar Sin mai yawan kamuwa da cutar sankara na ciki, yawan kamuwa da cutar Helicobacter pylori ya kai kashi 50%, kuma matsalar juriya na kwayoyin cuta na kara yin muni, wanda ke haifar da raguwar ci gaba a cikin adadin kawar da cutar.
Kwanan nan, ƙungiyar Farfesa Bi Hongkai, Makarantar Magungunan Asali, Jami'ar Kiwon Lafiya ta Nanjing, ta yi nasarar tantance sabon ɗan takarar miyagun ƙwayoyi don Helicobacter pylori-Dihydrotanshinone I. Dihydrotanshinone I na da fa'idodin babban inganci da saurin kashe Helicobacter pylori, anti - Helicobacter pylori biofilm, aminci da juriya ga juriya, da sauransu, kuma ana tsammanin zai shiga bincike na musamman a matsayin ɗan takarar magungunan Helicobacter pylori. An buga sakamakon a yanar gizo a cikin mujallar antimicrobial na duniya mai ƙarfi mai ƙarfi "Magungunan Kwayoyin cuta da Magungunan Jiki".

Adadin rashin nasarar farko na jiyya na magungunan gargajiya shine kusan 10%

A karkashin madubin dubawa, tsayinsa shine kawai micrometers 2.5 zuwa 4 micrometers, kuma fadin kawai 0.5mrometer zuwa 1 micrometers. Helicobacter pylori, ƙwayoyin cuta masu lanƙwasa da ke “yaɗa hakora da raye raye”, ba kawai zai iya haifar da gastritis mai ƙima ba, na ciki da duodenal ulcers da lymphatics. Cututtuka kamar su lymphoma na ciki na yaduwa suma suna da alaƙa da ciwon daji na ciki, ciwon hanta, da ciwon sukari.

Sau uku da sau huɗu da ke ɗauke da maganin rigakafi guda biyu ana yawan amfani da su a ƙasata don kula da Helicobacter pylori, amma hanyoyin maganin gargajiya ba za su iya kawar da Helicobacter pylori ba.

“Matsalar rashin nasarar farkon maganin maganin gargajiya shine kusan kashi 10%. Wasu marasa lafiya za su sami zawo ko cututtukan flora na ciki. Wasu suna rashin lafiyar penicillin, kuma akwai ƙarancin maganin rigakafi da za a zaɓa daga. A lokaci guda, yin amfani da maganin rigakafi na dogon lokaci zai haifar da ƙwayoyin cuta Ci gaban juriya na miyagun ƙwayoyi yana sa ingancin maganin ya yi muni, kuma ba za a iya cimma nasarar kawar da komai ba. ” Bi Hongkai ya ce: “Kwayoyin cuta suna tsayayya da wasu maganin rigakafi, kuma su ma za su kasance masu juriya ga sauran maganin rigakafi, kuma juriya na iya bambanta ta hanyoyi daban -daban. Kwayoyin cuta suna yaɗuwa da juna ta hanyar kwayoyin halittar da ba ta da magani, wanda ke rikitar da juriya na ƙwayoyin cuta. ”

Lokacin da Helicobacter pylori ya ƙi mamaye mamayar maƙiyi, da wayo zai samar da “murfin kariya” na biofilm, kuma biofilm ɗin zai sami juriya ga maganin rigakafi, wanda ke haifar da ƙaruwa ga Helicobacter pylori, yana shafar tasirin warkewa da rage ƙimar warkarwa.

Gwajin gwajin salvia miltiorrhiza na iya hana nau'ikan magunguna masu yawa

A cikin 1994, Hukumar Lafiya ta Duniya ta ware Helicobacter pylori a matsayin mai cutar kanjamau na Class I saboda yana taka rawar gani a faruwar da haɓaka ciwon daji na ciki. Yadda za a kawar da wannan mai kisa na lafiya? A cikin 2017, ƙungiyar Bi Hongkai ta yi nasara ta hanyar gwajin farko-Danshen.

Danshen yana daya daga cikin magungunan gargajiya na kasar Sin da aka fi amfani da su don inganta zagayowar jini da cire tsayayyen jini. Abubuwan da ke fitar da mai mai narkewa sune mahaɗan tanshinone, gami da sama da monomers 30 kamar tanshinone I, dihydrotanshinone, tanshinone IIA, da cryptotanshinone. Tanshinone mahadi suna da nau'ikan magunguna daban-daban, kamar maganin cutar kansa, ƙwayoyin cuta masu cutarwa, anti-mai kumburi, aikin estrogen-like da kariya ta zuciya, da sauransu, amma ba a ba da rahoton tasirin Helicobacter pylori ba.

"A baya, mun bincika sama da masu binciken likitancin Sin sama da 1,000 a matakin sel, kuma a ƙarshe mun ƙaddara cewa dihydrotanshinone I monomer a Danshen yana da mafi kyawun sakamako a kashe Helicobacter pylori. Lokacin yin gwajin sel, mun gano cewa lokacin da aka yi amfani da maida hankali na dihydrotanshinone I Lokacin yana 0.125 μg/ml-0.5 μg/ml, zai iya hana ci gaban nau'o'in Helicobacter pylori da yawa, gami da ƙwayoyin cuta masu saurin kamuwa da ƙwayoyin cuta. . ” Bi Hongkai ya ce dihydrotanshinone I shima yana da tasiri sosai akan Helicobacter pylori a cikin sinadaran halittu. Kyakkyawan sakamako na kisa, kuma Helicobacter pylori bai haɓaka juriya ga dihydrotanshinone I yayin ci gaba da tafiya ba.

Babban abin mamakin shine “Lokacin da dihydrotanshinone na kashe Helicobacter pylori, ba zai iya lalata fim ɗin ba, har ma yana kashe ƙwayoyin cuta da ke haɗe da biofilm, wanda ke taka rawa wajen '' cire '' Helicobacter pylori. "Bi Hongkai ya gabatar.

Shin Dihydrotanshinone I na iya warkar da Helicobacter pylori?

Don yin sakamakon gwajin ya zama daidai, ƙungiyar Bi Hongkai ta kuma gudanar da gwajin gwaji a cikin beraye don ƙarin tantance tasirin kisan dihydrotanshinone I akan Helicobacter pylori.

Bi Hongkai ya gabatar da cewa a cikin gwajin, makwanni biyu bayan mice sun kamu da Helicobacter pylori, masu binciken sun raba su zuwa rukuni 3, wato ƙungiyar haɗin gwiwa ta omeprazole da dihydrotanshinone I, daidaitaccen tsarin gudanarwa sau uku, da phosphoric acid In ƙungiyar kula da buffer, an ba beraye magani sau ɗaya a rana don kwanaki 3 a jere.

"Sakamakon gwajin ya nuna cewa ƙungiyar haɗin gwiwar omeprazole da dihydrotanshinone I suna da ƙima mafi girma wajen kashe Helicobacter pylori fiye da daidaiton tsarin sau uku." Bi Hongkai ya ce, wanda ke nufin a cikin beraye, dihydrotanshinone I yana da mafi girman kisa fiye da magungunan gargajiya.

Yaushe Dihydrotanshinone zan shiga gidajen talakawa? Bi Hongkai ya jaddada cewa ba za a iya amfani da Danshen kai tsaye don hanawa da magance kamuwa da cutar Helicobacter pylori ba, kuma monomer dihydrotanshinone I har yanzu ba a sanya shi cikin maganin da za a iya amfani da shi na asibiti ba. Ya ce matakin na gaba zai ci gaba da nazarin tsarin aikin dihydrotanshinone I, da inganta magunguna da guba na dihydrotanshinone I akan Helicobacter pylori. “Hanyar da ke gaba har yanzu tana da tsawo. Ina fatan kamfanoni za su iya shiga cikin binciken kafin asibiti kuma su ci gaba da wannan binciken don amfanar da yawancin marasa lafiya da ke fama da ciwon ciki. ”